‘Copias’ de Ozempic se venden a 14 dólares: India lanza genéricos de semaglutida tras expirar la patente

The expiration of the patent for Ozempic (semaglutide) has led Indian pharmaceutical companies to launch generic versions priced as low as $14, potentially increasing accessibility in markets with high obesity rates but intensifying competition for the original manufacturer, Novo Nordisk. This development could erode profits for branded drug makers in the short term due to price pressures, while benefiting generic producers and consumers in emerging markets. However, as patent expirations are anticipated events, the broader market impact may be limited unless it signals wider trends in global pharma pricing.